Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

Young, Jim; Schäfer, Juliane; Fux, Christoph A; Furrer, Hansjakob; Bernasconi, Enos; Vernazza, Pietro; Calmy, Alexandra; Cavassini, Matthias; Weber, Rainer; Battegay, Manuel; Bucher, Heiner C; Swiss HIV Cohort Study, (2012). Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS, 26(5), pp. 567-75. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e32834f337c

Full text not available from this repository. (Request a copy)

Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

ISSN:

0269-9370

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:37

Last Modified:

17 Mar 2015 21:28

Publisher DOI:

10.1097/QAD.0b013e32834f337c

PubMed ID:

22398568

Web of Science ID:

000301333000006

URI:

https://boris.unibe.ch/id/eprint/14958 (FactScience: 222101)

Actions (login required)

Edit item Edit item
Provide Feedback